Gregory A. Schernecke

Gregory-Schernecke

Gregory A. Schernecke

Partner

Philadelphia | Cira Centre, 2929 Arch Street, Philadelphia, PA 19104-2808
+1 215 994 2687 | +1 215 994 2222

| vCard | PDF

Gregory A. Schernecke focuses his practice on mergers and acquisitions, with a particular emphasis on private equity; corporate finance and general corporate matters, including public company reporting and governance issues.

Mr. Schernecke represents strategic and private equity buyers and sellers and their portfolio companies in merger and acquisition transactions across a wide range of industry sectors, including travel and hospitality, technology, consumer products, financial services and asset management, healthcare and industrial manufacturing. He also represents companies and investment banks in cross border public and private financing transactions and securities offerings of debt and equity.

In 2014, Mr. Schernecke was part of the Dechert team that received “Standout” recognition in the Financial Times’ North America Innovative Lawyers 2014 awards. The team was recognized for its innovative representation of the Certares-led investor group in its joint venture with American Express Company for its Global Business Travel division valued at US$1.8 billion and related US$900 million investment. In addition, Mr. Schernecke was named a Rising Star for capital markets: equity in the IFLR1000.

Experience

Mergers & Acquisitions

  • Novadaq Technologies, Inc. (NASDAQ: NVDQ), a leading provider of proven comprehensive fluorescence imaging solutions for medical procedures, in its US$701 million sale to Stryker Corporation.
  • Lexmark International, Inc. a global imaging leader, in the sale of its Enterprise Software business to Thoma Bravo.
  • Travel Leaders Group, a travel management company managing leisure, business and franchise travel operations under a variety of diversified divisions and brands, in several acquisition transactions and related financing activities.
  • Kofax Limited (NASDAQ: KFX), a leading provider of smart process applications, in its US$1 billion sale to Lexmark International, Inc.
  • MWI Veterinary Supply, Inc. (NASDAQ: MWIV), the leading animal health distribution company in the United States, in its US$2.5 billion sale to AmerisourceBergen Corporation.
  • The Certares-formed investor group in connection with its joint venture with American Express Company for its Global Business Travel division and related US$900 million investment.
  • Court Square Capital Partners and MacDermid Incorporated, a specialty chemical company, in the US$1.8 billion sale of MacDermid Incorporated to Platform Acquisition Holdings Limited (LSE: PAH).
  • Evercore Partners as financial advisor to Clearwire in connection with Sprint Nextel Corporation’s US$3.8 billion acquisition of all of the Class A Common Stock of Clearwire.
  • One Equity Partners in its US$470 million acquisition of APAC Customer Services, Inc. (NASDAQ: APAC)
  • The Stripes Group in connection with its investments in Califia Farms, one of the fastest growing natural beverage companies in the United States, and Sandata Technologies, a leading provider of healthcare-related information technology solutions and services.
  • Brandywine Senior Living, Inc. in its US$610 million sale of 19 senior housing facilities to Health Care REIT Inc.

Domestic Capital Markets & Corporate Finance

  • Piper Jaffray & Co. as sole placement agent in the US$45.8 million equity financing by aTyr Pharma, Inc. (NASDAQ: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics.
  • Underwriters led by Piper Jaffray & Co. in the US$26 million CMPO by Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases.
  • Underwriters led by Piper Jaffray & Co. in the US$40 million follow-on offering by Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating, specialty pharmaceutical company primarily focused on developing innovative products for hospitals and ambulatory care settings.
  • Underwriters led by Stifel Nicolaus Weisel, Leerink Swann and Cowen & Company in the initial public offering of Cempra, Inc. (NASDAQ: CEMP) a clinical-stage pharmaceutical company. Subsequently advised the underwriters led by Barclays Capital, Stifel Nicolaus and Cowen & Company in a US$54.2 million follow-on public offering by Cempra, Inc.
  • Underwriters, led by Stifel and Lazard Capital Markets, in connection with the initial public offering of common stock by Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on animal health.
  • Bravo Brio Restaurant Group, Inc. (NASDAQ: BBRG) in its US$161 million initial public offering and US$74 million follow-on offering of common shares.
  • The underwriters in three follow-on public offerings by Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases.
  • The underwriters in multiple CMPO and At-The-Market offerings by Inovio Pharmaceuticals, Inc., a clinical stage company developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
  • Underwriters led by Piper Jaffray & Co. in the US$24 million and US$37 million CMPOs by Medgenics, Inc. (NYSE MKT: MDGN), a clinical stage rare and orphan disease company developing an innovative and proprietary ex vivo gene therapy platform.
  • Barclays Capital as sole book-running manager and Wedbush Securities Inc. and Griffin Securities as co-managers in the US$45.1 million public offering by Fibrocell Science, Inc., an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications.
  • Underwriters led by Leerink Swann and Cowen & Company in the US$54 million primary offering of Amicus Therapeutics, Inc. (NASDAQ: FOLD)
  • OraSure Technologies, Inc. (NASDAQ: OSUR) in its US$75 million primary offering of common stock and subsequent shelf registration.

Cross-Border Capital Markets & Corporate Finance

  • Underwriters led by JMP Securities in the US$28.75 million CMPO by BioLineRX Ltd (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology.
  • Underwriters led by Citigroup Global Markets Inc. and Jefferies LLC in the US$75 million initial public offering in the U.S. of Advanced Accelerator Applications S.A. (NASDAQ: AAAP)
  • Kofax® Limited, a leading provider of smart process applications, on its migration by way of scheme of arrangement to Bermuda, initial public offering in the U.S. and dual NASDAQ and LSE listing.
  • Novadaq Technologies, Inc. (NASDAQ: NVDQ) in its initial public offering in the United States pursuant to the Canadian/United States Multi-Jurisdictional System.
  • Underwriters led by Piper Jaffray & Co. and Wedbush Securities, Inc. in the US$32 million primary offering of Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Placement agents led by Piper Jaffray & Co. in the private placement of common shares and warrants by Nanobiotix (EURONEXT: NANO), a clinical-stage French nanomedicine company working on the local treatment of cancer.
  • Placement agents led by Piper Jaffray & Co. in the €30 million private placement of common shares by argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company.
Education
  • Davidson College, B.A., 2003
  • Temple University Beasley School of Law, J.D., 2008, magna cum laude
Admissions
  • Pennsylvania
Memberships
  • Philadelphia Bar Association Young Lawyers Division